^
    3ms
    HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P3, N=104, Terminated, Hinova Pharmaceuticals USA, Inc. | Trial completion date: Dec 2024 --> Jun 2024 | Active, not recruiting --> Terminated; Terminated by Sponsor for various factors including prolonged duration and enrollment challenges
    Trial completion date • Trial termination • Head-to-Head • Metastases
    |
    Xtandi (enzalutamide capsule) • deutenzalutamide (HC-1119)
    11ms
    HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P3, N=104, Active, not recruiting, Hinova Pharmaceuticals USA, Inc. | Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Head-to-Head • Metastases
    |
    Xtandi (enzalutamide capsule) • deutenzalutamide (HC-1119)
    2years
    HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells. (PubMed, Mol Biol Rep)
    Importantly, cotreatment with HC-1119 of these cells efficiently abolished all of these effects of DHT on both Hs578T and SUM159PT cells. These results indicate that HC-1119 is a very effective new second-generation AR antagonist that can inhibit the migration, invasion and metastasis of the AR-positive TNBC cells.
    Journal
    |
    ER (Estrogen receptor) • AR (Androgen receptor)
    |
    AR positive • AR expression
    |
    deutenzalutamide (HC-1119)